Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntReALL SR 2010: Chemotherapy Optimization and Epratuzumab in Relapsed Childhood ALL
NCT01802814Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2014
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of epratuzumab in acute lymphoblastic leukemia (ALL) (4 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Event-Free Survival up to 9 years. Started May 2014; status: completed.
02
Drugs
epratuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01802814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802814.